Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Radhika Amaradhi

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry|November 8, 2020
Azaindole therapeutic agentsDamoder Reddy Motati, Radhika Amaradhi, Thota Ganesh
ACS Chemical Neuroscience|April 24, 2020
An Agonist Dependent Allosteric Antagonist of Prostaglandin EP2 ReceptorsChunxiang Jiang, Radhika Amaradhi, Thota Ganesh, et al.
Antioxidants (Basel, Switzerland)|September 28, 2023
Novel NADPH Oxidase-2 Inhibitors as Potential Anti-Inflammatory and Neuroprotective AgentsMatea Juric, Varun Rawat, Radhika Amaradhi, et al.
Molecular Pharmaceutics|November 7, 2018
Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory PropertiesThota Ganesh, Avijit Banik, Ray Dingledine, et al.
ACS Pharmacology & Translational Science|February 21, 2022
Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory PropertiesRadhika Amaradhi, Shabber Mohammed, Avijit Banik, et al.
ACS Chemical Neuroscience|January 2, 2026
Antagonism of the EP2 Receptor Reveals Sex-Specific Protection in a Two-Hit Mouse Model of Alzheimer's DiseaseAvijit Banik, Radhika Amaradhi, Michael Sau, et al.
Journal of Neuroinflammation|November 21, 2021
Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's diseaseAvijit Banik, Radhika Amaradhi, Daniel Lee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 29, 2022
Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal modelsVarun Rawat, Avijit Banik, Radhika Amaradhi, et al.
Journal of Virology|March 31, 2025
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infectionRoshan Ghimire, Rakshya Shrestha, Radhika Amaradhi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 7, 2021
A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in RatsAsheebo Rojas, Radhika Amaradhi, Avijit Banik, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry|November 8, 2020
Azaindole therapeutic agentsDamoder Reddy Motati, Radhika Amaradhi, Thota Ganesh
ACS Chemical Neuroscience|April 24, 2020
An Agonist Dependent Allosteric Antagonist of Prostaglandin EP2 ReceptorsChunxiang Jiang, Radhika Amaradhi, Thota Ganesh, et al.
Antioxidants (Basel, Switzerland)|September 28, 2023
Novel NADPH Oxidase-2 Inhibitors as Potential Anti-Inflammatory and Neuroprotective AgentsMatea Juric, Varun Rawat, Radhika Amaradhi, et al.
Molecular Pharmaceutics|November 7, 2018
Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory PropertiesThota Ganesh, Avijit Banik, Ray Dingledine, et al.
ACS Pharmacology & Translational Science|February 21, 2022
Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory PropertiesRadhika Amaradhi, Shabber Mohammed, Avijit Banik, et al.
ACS Chemical Neuroscience|January 2, 2026
Antagonism of the EP2 Receptor Reveals Sex-Specific Protection in a Two-Hit Mouse Model of Alzheimer's DiseaseAvijit Banik, Radhika Amaradhi, Michael Sau, et al.
Journal of Neuroinflammation|November 21, 2021
Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's diseaseAvijit Banik, Radhika Amaradhi, Daniel Lee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 29, 2022
Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal modelsVarun Rawat, Avijit Banik, Radhika Amaradhi, et al.
Journal of Virology|March 31, 2025
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infectionRoshan Ghimire, Rakshya Shrestha, Radhika Amaradhi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 7, 2021
A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in RatsAsheebo Rojas, Radhika Amaradhi, Avijit Banik, et al.
Pageof 2